The review aimed to assess whether SGLT2 inhibitors or pioglitazone provide superior outcomes in terms of efficacy and safety. Based on our analysis, we have discovered that SGLT2 inhibitors and pioglitazone are promising treatments for NAFLD/NASH. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.